Table 1 HPV prevalence and genotype distribution in women with and without cervical abnormalities

Population-Based studies

Serwadda et al., 1999 [52]

Rakai district, Random sample of 960 women aged 15-59 years using self collected vaginal swabs

Cross-sectional

Hybrid Capture 2

Any HR-HPV^a, 16.7%

HIV status ^a

HIV+, 44.3%

HIV-, 10.2%

HIV prevalence^a, 17.8%

Safaeian et al., 2007 [53]

Rakai district, 606 women, median age 30 years (25-38 years)

Baseline of a population-based cohort study

Hybrid Capture 2/PGMY 09/11 assay

Any HR-HPV^a, 19%

Type-specific genotypes ^a

HPV 16, 4.5%

HPV 52, 4.4%

HPV 66, 3.0%

HPV 58, 3.0%

HIV status ^a

HIV positive

Self-collected, 40%

Physician collected, 37%

HIV negative

Self-collected, 15%

Physician collected, 16%

HIV prevalence^a, 15.7%

Asiimwe et al., 2008 [21]

Bushenyi district, 314 women with median age of 27 years (range,18-49) using self collected vaginal swabs

Cross-sectional

Hybrid Capture 2 assay

Any HR-HPV^a, 17.2%

HIV prevalence^a, 5.6% (self-reported)

Safaeian et al., 2008b [20]

Rakai district, 926 sexually exprienced women aged 15-49 years, mean age 26 years, who provided at least 3 consecutive self-collected swabs

Population-based cross-sectional study

Hybrid Capture 2/Prototype Roche reverse line blot assay

Any HR-HPV^a, 19.2%

Type-specific genotypes ^a

HPV 52, 2.2%

HPV 16, 2.1%

HPV 51, 1.7%

HPV 66, 1.5%

HPV 68, 1.3%

HIV status ^a

HIV+, 46.6%

HIV-, 14.8%

HIV prevalence^a, 13.7%

Clinic-Based Studies

Adult women

Blossom et al., 2007 [17]

STI clinic in Kampala, 106 women mean age 26.3 years (range,18-51)

Cross-sectional

Roche PCR/reverse strip assay

Any HPV^a, 46.2%

Type-specific genotypes ^b

HPV 16/18, 18.4%

HPV 52, 14.2%

HPV 16, 7.5%

HPV 58, 7.5%

Any HPV type ^a

HIV+, 59.5%

HIV-, 39.1%

HR-HPV types ^b

HIV+, 100.0%

HIV-, 88.9%

HIV prevalence^a, 34.9%

Young women below 25 years

Banura et al., 2008a [16]

Clinic for teenagers in Kampala, 1275 sexually active young women median age 20 years (range 12-24)

Baseline of a cohort study

SPF₁₀/LIPA PCR assay

Any HPV^a, 74.6%

HR-HPV types^a, 51.4%

Type-specific genotypes ^a

HPV 52, 13.2%

HPV 51, 12.3%

HPV 18, 10.7%

HPV 16, 10.6%

LR-HPV types^a, 39.8%

LR-HPV genotypes ^a

HPV 6, 15.5%

HPV 11, 13.3%

HIV positive women

Any HPV^a, 87.8%

HR-HPV types, 67.1%

Type-specific genotypes ^a

HPV 16, 18.3%

HPV 18, 9.8%

HPV 6, 15.9%

HPV 11, 17.1%

HIV negative women

Any HPV^a, 73.2%

HR-HPV types^a, 49.7%

Type-specific genotypes ^a

HPV 16, 10.7%

HPV 18, 12.1%

HPV 6, 15.3%

HPV 11, 12.7%

HIV prevalence^a, 8.6%

Banura et al., 2008b [18]

Antenatal clinic in Kampala

987 young primiparous pregnant women, median age 19 years (range 14-24)

Baseline of a cohort study

SPF₁₀/LIPA PCR assay

Any HPV^a, 60.0%

High-risk types^b, 43.0%

Type-specific genotypes ^b

HPV 52, 12.1%

HPV 51, 8.7%

HPV 16, 8.4%

HPV 18, 5.8%

LR-HPV genotypes

LR-HPV types^b, 23%

Type-specific genotypes ^b

HPV 6, 5.5%

HPV 11, 3.2%

HIV positive women

Any HPV^a, 72.2%

Type-specific genotypes ^b

HPV 16, 18.1%

HPV 18, 6.9%

HPV 6, 8.3%

HPV 11, 1.4%

HIV negative women

Any HPV^a, 58.9%

Type-specific genotypes ^b

HPV 16, 7.7%

HPV 18, 5.7%

HPV 6, 5.3%

HPV 11, 3.4%

HIV prevalence^a, 7.3%

Screened adult women

Buonaguro et al., 2000 [54]

Nsambya hospital, Scrapes of 16 women with normal ecto-cervical epithelium and different degrees of cervical epithelial lesions

Cross-sectional

Southern Blot analysis

HPV 16^a, 12.5%

Taube et al., 2010 [19]

Post-natal clinic at Mulago hospital, Kampala

Cervical exfoliated cells from 196 women, 4-12 weeks post-partum and aged between 18-30 years (mean age for HIV -23 ± 3; HIV + 25.4 ± 3.2)

Cross-sectional

Roche Linear array assay

Any HR-HPV^a, 49.0%

HPV 16/18^a, 24%

HR-HPV types ^a

HPV 16, 8.2%

HPV 18, 3.5%

HPV 45, 5.1%

HPV 58, 5.1%

LR-HPV types ^a

HPV 6, 2.6%

HPV 11, 1.0%

HIV positive

Any HR-HPV^a, 77.8%

Type-specific genotypes ^a

HPV 16, 13.9%

HPV 18, 5.6%

HPV 45, 8.3%

HPV 58, 5.6%

Other HR-HPV, 47.2%

LR-HPV types

HPV 6, 5.6%

HPV 11, 2.8%

HIV negative

Any HR-HPV^a, 42.5%

Type-specific genotypes ^b

HPV 16, 6.9%

HPV 18, 3.1%

HPV 45, 4.4%

HPV 58, 5.0%

Other HR-HPV, 30.6%

HIV prevalence^a, 18.0%